Antibiotics or Placebo? The Effectiveness & Cost of Treating Children with Lower Respiratory Tract Infection

By Danélia Botes

July 25, 2023

Antimicrobial drug resistance is a growing public health problem, particularly in relation to respiratory tract infections (RTIs) which are commonly treated in primary care. Antibiotic resistance is linked to primary care antibiotic prescribing and has significant cost implications. Despite a decrease in consultation and prescription rates for RTIs from the late 1990s to early 2000s, antibiotic use has fluctuated, rising again during the COVID-19 pandemic. Children have higher consultation rates for RTIs and are often prescribed antibiotics, even when these prescriptions are at their lowest. There is limited evidence to support the use of antibiotics for chest infections in children, and differences between adults and children mean adult-derived evidence cannot be directly applied. Both parents and clinicians have concerns about illness progression and potential adverse outcomes. The study aimed to assess the effectiveness of amoxicillin in children with uncomplicated lower respiratory tract infection.


A total of 432 children participated in this study- found that amoxicillin for uncomplicated lower respiratory tract infections in children is unlikely to be clinically effective or to reduce health or societal costs. The duration of symptoms was similar in the antibiotic and placebo groups, as were the rates of consultations, illness progression, and side effects. The costs per child to the NHS were slightly higher for antibiotics, but there was no difference in non-NHS costs. The study concluded that parents need better access to information and clear communication about managing their child’s illness. Clinicians also noted a reduction in parents’ expectations for antibiotics.

The study also found that the costs to the NHS per child were similar for both antibiotics and placebo (£29 vs £26), and societal costs were the same (£33). In the study they suggest that GPs should support parents to self-manage at home and provide clear communication about when and how to seek medical help. Parents whose children received antibiotics reported symptoms as moderately bad or worse for 5 days, while those given a placebo reported symptoms for 6 days. Side effects were similar in both groups. The study concluded that amoxicillin for chest infections in children is unlikely to be effective, and recommended that GPs support parents to self-manage at home while providing clear communication about when and how to seek medical help.

Reference url

Recent Posts

Cost and clinical impact of MIS-C

Understanding the Cost and Clinical Impact of Multisystem Inflammatory Syndrome in Children (MIS-C)

🔍 Discovering the Economic Impact of Multisystem Inflammatory Syndrome in Children (MIS-C) 🏥💰

Understanding the cost and clinical impact of MIS-C during COVID-19 is crucial for healthcare providers and policymakers. Learn about treatment costs, patient outcomes, and key statistics related with MIS-C.

🌟#Healthcare #MIS-C #COVID19 #Pediatrics #HealthEconomics #MedicalResearch #HealthcareResearch #MedicalEconomics 📊

Let’s navigate the intersection of healthcare and economics together! 💼 #HealthcareInsights #EconomicAnalysis 🧠


Striking the Balance: Optimising Hepatitis B Treatment Strategies in The Gambia

Hepatitis B continues to pose a significant public health challenge, but the World Health Organization continues to work towards achieving their ambition of eliminating HBV as a public health problem by 2030.

One strategy is the Treat All approach, which sounds promising – however, in low-resource settings implementing promising strategies becomes more complex. This study explores striking the balance between promising strategies and getting people the treatment they need.

Learn more about innovative HBV treatment approaches and their impact on global health. Stay informed and join the conversation! 💡🔬 #HealthcareInnovation #HBVResearch

cost effectiveness multiple sclerosis

Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Exploring the Cost-Utility of MS Treatments: A Comprehensive Review 🧠💼 Dive into the latest findings on the cost-effectiveness of Disease-Modifying Drugs for Multiple Sclerosis. Discover key insights and recommendations for optimizing treatment strategies. #MSresearch #HealthcareEconomics #Neurology #HealthTech 📊🔬

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.